Current Partnering Best Practice for Dealmakers
  • Home
  • Reports
    • Expert reports
    • Deal type reports
    • Deal review reports
    • Technology reports
    • Therapy reports
      • Oncology partnering reports
      • Cardiovascular partnering reports
      • CNS partnering reports
      • Metabolic partnering reports
      • Psychiatry partnering reports
    • Company reports
    • Dealdocs
      • Dealdocs: Partnering
      • Dealdocs: M&A
    • Marketplace
      • Royalty reports
      • Strategy reports
      • Therapy-based reports
      • Technology type reports
      • Geographic reports
      • Company reports
      • Other
    • Store Affiliates
      • Register
    • Offers
  • Services
    • Current Agreements
    • Deal Tracker
    • Therapy Tracker
    • Technology Tracker
    • Deals on Demand
    • Dealmaker’s Knowledge Centre
  • Insight
    • Articles
    • Points of view
    • Glossary
    • Top 50 Pharma
  • News
    • Partnering
    • M&A
    • Financing
    • Dealtalk
  • Events
    • Featured events
    • Partnering
    • Conferences
    • Training
    • Exhibitions
  • Scorecard
    • Partnering scorecard
    • M&A scorecard
    • Financing scorecard
    • Bigpharma dealmaking
    • R&D spending
    • Deal metrics
  • About Us
    • The people
    • Press releases
    • In the media
    • Sponsors
    • Advertising options
    • License type definitions
    • Terms & conditions / privacy
  • Contact Us
    • Enquiry
    • Subscribe

Subscribe via: RSS

Top 50 Pharma

Here you will find a comprehensive listing of the top pharmaceutical companies of 2011, by revenue.

  1. Pfizer
  2. Novartis
  3. Sanofi
  4. Merck & Co.
  5. Roche
  6. GlaxoSmithKline (GSK)
  7. AstraZeneca (AZ)
  8. Johnson & Johnson (J&J)
  9. Eli Lilly (Lilly)
  10. Abbott
  11. Bristol-Myers Squibb (BMS)
  12. Teva
  13. Amgen
  14. Bayer
  15. Takeda
  16. Boehringer Ingelheim
  17. Novo Nordisk
  18. Astellas
  19. Daiichi Sankyo
  20. Eisai
  21. Merck KGaA
  22. Gilead Sciences
  23. Baxter
  24. Mylan
  25. Servier
  26. Chugai
  27. Mitsubishi Tanabe
  28. Menarini
  29. Genzyme
  30. Allergan
  31. Forest
  32. CSL
  33. UCB
  34. Otsuka
  35. Celgene
  36. Biogen Idec
  37. Shire
  38. Alcon
  39. Warner Chilcott
  40. Cephalon
  41. Watson
  42. Lundbeck
  43. Kyowa Hakko Kirin
  44. Dainippon Sumitomo
  45. Shionogi
  46. Actavis
  47. Hospira
  48. Nycomed
  49. Apotex
  50. Stada

 

bannerpng
china-bio-2012jpg
molecular-diagnostics-june-2012jpg
  • Latest News
  • Popular
  • Latest Comments
  • Amag Pharma falls after ending sale talks
  • OncoMed seeks $115 million IPO
  • BMS and Tsinghua University in structural biology research pact
  • Menarini licenses rights to Priligy
  • The trouble with tech M&A
  • Top twenty partnering deals of 2011 have a combined value of over $21 billion
  • The Hep C club: the new dealmakers hot spot
  • Vical and Teva Pharmaceutical establish sales and marketing agreement for Allovectin-7(r) in Israel
  • Biopharma partnering: Perspectives from BCG’s latest biotech and pharma partnering study
  • Biotech investing at a crossroads?
  • Steve Poile: HI Beverly Sure, your email address is added an...
  • Beverly Cormier: This is a great report. I would to receive it via...
  • Rob Grundy: Hi Bruce, Great article. 'Let me frame up tw...
  • Joe Patti: Jan. 24, 2012-BioLineRx signed an “exclusive licen...
  • Steve Poile: Hi Kevin Thanks for this. I believe it is alrea...

Latest Tweets

  • Amag Pharma falls after ending sale talks | Current Partnering: http://t.co/nyrVHlXR 2 days ago
  • OncoMed seeks $115 million IPO | Current Partnering: http://t.co/KbAVxQHF 2 days ago

Home | Reports | Services | Insight | News | Events | Scorecard | About us | Terms & conditions | Subscribe | Contact us © 2012 Wildwood Ventures Ltd.